Incyte (LTS:0J9P) Inventories, Other : $64 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Incyte Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Incyte's other inventories for the quarter that ended in Mar. 2025 was $64 Mil.

Incyte's quarterly other inventories declined from Sep. 2024 ($70 Mil) to Dec. 2024 ($59 Mil) but then increased from Dec. 2024 ($59 Mil) to Mar. 2025 ($64 Mil).

Incyte's annual other inventories increased from Dec. 2022 ($42 Mil) to Dec. 2023 ($63 Mil) but then declined from Dec. 2023 ($63 Mil) to Dec. 2024 ($59 Mil).

Incyte Inventories, Other Historical Data

The historical data trend for Incyte's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Inventories, Other Chart

Incyte Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Other

Get a 7-Day Free Trial

16.43

27.90

42.00

62.97

58.87

Incyte Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Inventories, Other	Get a 7-Day Free Trial															63.64	100.70	70.44	58.87	63.98

Incyte Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

INCY:USA INCY:Mexico 1INCY:Italy ICY:Germany ICY:Germany

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines